Francis Lo Sells 38,074 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Key Points

• Insider sale: Francis Lo sold 38,074 shares on March 5 at an average of $15.09 for about $574,537, trimming his stake by 10.57% to 321,967 shares; he has made several other large sales this year (e.g., 79,590 on Jan 12 and 113,890 on Dec 15).
• Quarterly results: Adaptive Biotechnologies beat estimates with EPS of -$0.09 (vs. -$0.19 expected) and revenue of $71.7M (vs. $59.4M), a 51% year-over-year revenue gain, though the company remains unprofitable with a ~21.5% negative net margin.
• Market and analyst view: Shares traded at $14.95 (+0.6%) midday with a $2.30B market cap; analysts show a consensus "Moderate Buy" and a $18.25 price target, while 50-/200-day moving averages are $16.76 and $15.87 respectively.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 38,074 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $15.09, for a total value of $574,536.66. Following the transaction, the insider owned 321,967 shares in the company, valued at $4,858,482.03. This trade represents a 10.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Francis Lo also recently made the following trade(s):

• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.08, for a total value of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.50, for a total value of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total value of $1,773,267.30.

Adaptive Biotechnologies Stock Up 0.6%

Shares of NASDAQ:ADPT traded up $0.09 during midday trading on Monday, reaching $14.95. The company's stock had a trading volume of 3,493,266 shares, compared to its average volume of 1,536,238. The firm has a 50 day moving average of $16.76 and a 200-day moving average of $15.87. The firm has a market capitalization of $2.30 billion, a P/E ratio of -37.37 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to analysts' expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies's revenue was up 51.0% on a year-over-year basis. During the same period last year, the company posted ($0.23) EPS. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

ADPT has been the topic of several analyst reports. TD Cowen reissued a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Wall Street Zen cut shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an "equal weight" rating and a $21.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its holdings in shares of Adaptive Biotechnologies by 45.8% during the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock valued at $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock worth $511,000 after acquiring an additional 2,914 shares during the period. Caxton Associates LLP purchased a new stake in Adaptive Biotechnologies during the first quarter valued at $93,000. Envestnet Asset Management Inc. bought a new position in Adaptive Biotechnologies in the second quarter valued at about $467,000. Finally, Savant Capital LLC lifted its holdings in Adaptive Biotechnologies by 15.4% in the second quarter. Savant Capital LLC now owns 39,665 shares of the company's stock valued at $462,000 after acquiring an additional 5,305 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.